title: No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
abstract: Prior studies suggested that the use of androgen deprivation therapy (ADT) in patients with prostate cancer (PC) might cause the impairment of cognitive function which is one of the common symptoms of dementia; however, the association between ADT and cognitive impairment still remains controversial. This retrospective cohort study aimed to investigate the relationship between ADT and subsequent risk of dementia using a population-based dataset. Data for this study were taken from the Taiwan (China)Longitudinal Health Insurance Database 2005. We included 755 PC patients who received ADT in the study cohort and 559 PC patients who did not receive ADT in the comparison cohort. Each patient was individually tracked for a 5-year period to define those who subsequently received a diagnosis of dementia. Results show that the incidence rates of dementia per 100 person-years were 2.35 (95% confidence interval [95% CI]: 1.82-2.98) and 1.85 (95% CI: 1.35-2.48) for PC patients who received ADT and those who did not receive ADT, respectively. The adjusted hazard ratio (HR) for dementia for PC patients who received ADT was 1.21 (95% CI: 0.82-1.78, P = 0.333) compared to those who did not receive ADT. In addition, the adjusted HRs for dementia for PC patients receiving ADT with gonadotropin-releasing hormone (GnRH) agonists and without GnRH agonists were 1.39 (95% CI: 0.80-2.40, P = 0.240) and 1.13 (95% CI: 0.75-1.71, P = 0.564), respectively, compared to PC patients not receiving ADT. We concluded that there was no difference in the risk of subsequent dementia between PC patients who did and those who did not receive ADT.
authors.affiliation: Graduate Institute of Life Science, National Defense Medical Center, Taipei 110, Taiwan, China.|Sleep Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan, China.
authors.forename: Li-Ting
authors.initials: LT
authors.lastname: Kao
authors.affiliation: Sleep Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan, China.
authors.forename: Herng-Ching
authors.initials: HC
authors.lastname: Lin
authors.affiliation: Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Taipei 110, Taiwan, China.|Graduate Program in Biomedical Informatics, College of Informatics, Yuan-Ze University, Chung-Li 320, Taiwan, China.
authors.forename: Shiu-Dong
authors.initials: SD
authors.lastname: Chung
authors.affiliation: Department of Urology, National Taiwan University Hospital, College of Medicine National Taiwan University, Taipei 110, Taiwan, China.|School of Public Health, Taipei Medical University, Taipei 110, Taiwan, China.
authors.forename: Chao-Yuan
authors.initials: CY
authors.lastname: Huang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D016208:Databases, Factual; D003704:Dementia / Q000453:epidemiology* / Q000209:etiology / Q000523:psychology*; D005500:Follow-Up Studies; D013007:Growth Hormone-Releasing Hormone / Q000819:agonists; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy*; D012189:Retrospective Studies; D012306:Risk; D013624:Taiwan / Q000453:epidemiology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D013007:Growth Hormone-Releasing Hormone